LATEST PRESS RELEASES
Allogene Therapeutics Announces Encore Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the European Hematology Association (EHA) Hybrid Congress
ALLOGENE ON TWITTER: COMMUNITY GUIDELINES
THANK YOU FOR VISITING THE ALLOGENE TWITTER FEED!
Our Twitter feed is a place for community members to connect and learn about Allogene. Our goal is to provide useful and interesting content about our company.
Since we work in a regulated industry with a unique legal situation in the healthcare space, we can’t engage in sensitive topics or discussion(s) about our product candidates, clinical trials, financials, or any legal or regulatory matters.
We do not and cannot provide medical advice. Any questions regarding your condition, treatment, or medical side effects should be immediately directed to your physician or other healthcare professional.
Twitter accounts that @AllogeneTx follows or is followed by are not an indication of Allogene’s endorsement of these accounts or the content they produce. In addition, we may tweet links to certain websites or other content that are not created or controlled by us. We cannot attest to the accuracy of the linked information. We are also not endorsing the information presented in the linked content.
ALLOGENE THERAPEUTICS, INC., FORWARD-LOOKING STATEMENTS
Our tweets may contain forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The tweets may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: expectations regarding the clinical effectiveness and safety of our product candidates, the timing and ability of obtaining regulatory approval and commercially launching any product candidate, the ability to research and develop additional product candidates, and our ability to manufacture and deliver our product candidates.
Various factors may cause differences between our expectations and actual results as discussed in greater detail in our filings with the Securities and Exchange Commission, including without limitation in our most recent Form 10-K and Form 10-Q. Any forward-looking statements that are made speak only as of the date of the tweet. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of any tweet.
Thank you for reading and for following @AllogeneTx on Twitter.